alnylam
The Associate Director, Quantitative Systems Pharmacology supports a rapidly expanding clinical portfolio of RNAi therapeutics by applying QSP modeling and simulation to answer key drug development questions. This role involves strategizing and executing modeling approaches for dose selection, trial design, and predicting clinical outcomes while collaborating with cross-functional R&D teams. The position requires strong scientific curiosity, critical thinking, and the ability to work independently in a matrixed environment.
Headquarters
Cambridge, Massachusetts, United States
Company Size
1001-5000 employees
Founded
2002
Alnylam is a biopharmaceutical company that has pioneered RNA interference (RNAi) therapeutics, an innovative class of medicines that treats diseases by silencing the genes that cause or contribute to them. The company develops RNAi-based medicines targeting both rare and prevalent diseases across multiple therapeutic areas, with approved products and a robust investigational pipeline. Driven by science and inspired by patients, Alnylam is committed to delivering transformational medicines that address diseases at their genetic source.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for alnylam.
Associate Director, Clinical Pharmacology & Pharmacometrics
Dianthus Therapeutics
Associate Director, Clinical Pharmacology
Eikon Therapeutics
Principal Scientist - Clinical Pharmacology, Modeling & Simulation
Amgen
Postdoctoral Fellow, Quantitative Systems Pharmacology
Pfizer
Principal Scientist II/Senior Principal Scientist, Modeling & Simulation (Dual Level Posting)
Novartis
Senior Manager, Pharmacometrics, Clinical Pharmacology
Travere Therapeutics